𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of lymph node metastases assessment With the use of USPIO-enhanced MR imaging at 1.5 T versus 3.0 T in a rabbit model

✍ Scribed by Seung Hong Choi; Keon Ha Kim; Woo Kyung Moon; Hyo-Cheol Kim; Joo Hee Cha; Jin Ho Paik; Kee-Hyun Chang

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
361 KB
Volume
31
Category
Article
ISSN
1053-1807

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Purpose:

To prospectively compare the diagnostic performances of 1.5 T and 3.0 T ultrasmall superparamagnetic iron oxide (USPIO)‐enhanced magnetic resonance imaging (MRI) for the detection of lymph node (LN) metastases in a rabbit model.

Materials and Methods:

Experiments were approved by the animal care committee. VX2 carcinomas were implanted into the thighs of 18 rabbits 3 or 4 weeks before MRI examinations. T2*‐weighted 1.5 T and 3.0 T MRI was performed 24 hours after USPIO (2.6 mg/kg iron) administration. Two radiologists calculated signal intensity (SI) ratios (ie, the ratios of postcontrast to precontrast signal intensity) of each LN and also evaluated for the presence of a metastasis in the iliac and retroperitoneal LNs at 1.5 T and 3.0 T MRI. Student's t‐test, receiver operating characteristic (ROC) curve analysis, and a Z test were used for the statistical analysis.

Results:

Metastases were confirmed in 45 of 80 LNs by histopathology. For benign LNs the mean SI ratio at 1.5 T was higher (0.538) than at 3.0 T (0.463) (P = 0.004). In qualitative analysis, 1.5 T and 3.0 T USPIO‐enhanced MRI showed similar Az values (0.951 vs. 0.939; P = 0.296). The specificity of 3.0 T USPIO‐enhanced MRI was higher (91.4% [32 of 35]) than that of 1.5 T imaging (82.9% [29 of 35]) (P = 0.013); however, the sensitivities (88.9% [40 of 45]) were the same in the both modalities.

Conclusion:

3.0 T USPIO‐enhanced MRI shows a higher specificity as compared to 1.5 T imaging without a significant difference of sensitivity in a rabbit VX2 model. J. Magn. Reson. Imaging 2010;31:134–141. © 2009 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Enhancement effects of hepatic dynamic M
Enhancement effects of hepatic dynamic MR imaging at 3.0 T and 1.5 T using gadoxetic acid in a phantom study: comparison with gadopentetate dimeglumine
✍ Kosuke Morita; Tomohiro Namimoto; Kazuo Awai; Masanori Komi; Masahiro Hashida; T 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB

## Abstract To identify the optimum sequence at gadoxetic acid enhanced hepatic dynamic magnetic resonance imaging in the arterial phase, we studied phantoms that contained gadoxetic acid or gadopentetate dimeglumine diluted in human blood. We obtained magnetic resonance images at 3.0 T and 1.5 T w

Erratum to: Morita, et al., Enhancement
Erratum to: Morita, et al., Enhancement effects of hepatic dynamic MR imaging at 3.0 T and 1.5 T using gadoxetic acid in a phantom study: Comparison with gadopentetate dimeglumine
📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

The Fig. 3 was incorrect. It was same as the FIG. 2. The error had been made during the last stages of submitting publication-quality figures. The reviewers had seen the correct figure. The correct figure and legend is reprinted below. FIG. 3. Plots of the contrast ratio of the Gd concentrations at

Evaluation of gadobutrol, a macrocyclic,
Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: Comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T
✍ Ulrike I. Attenberger; Val M. Runge; John N. Morelli; Jonathan Williams; Carney 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 1 views

## Abstract ## Purpose: To evaluate in a rat brain glioma model intraindividual tumor enhancement at 1.5 T using gadobutrol (Gadovist), a nonionic, macrocyclic chelate currently in clinical trials in the United States, in comparison with both an ionic macrocyclic chelate, gadoterate meglumine (Dot